News – Page 1153 – Endpoints News

SIGN UP

Let's rethink Clinton's war on pharma; The FDA can't order the genie back into the magic lamp

9 years ago

Porges to Biogen: I don’t like your neuropathic pain drug; Ex-Moderna exec Bolen joins PureTech as CSO

9 years ago

Cerecor’s $1M Lilly deal put it in the right place at the right time today

9 years ago

Roche adjusts Avastin franchise defense plans as PhII successor fails a key study

9 years ago

Hot on the heels of its Bristol-Myers slapdown, Merck scores PhIII bladder cancer success with Keytruda

9 years ago

Alkermes plots course to the FDA after its depression drug scores success in last-stand PhIII

9 years ago

Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that

9 years ago

Investors add $17M to Emulate Series B as Covance partners; UMass professor to work with Spark on next-gen vectors

9 years ago

Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round

9 years ago

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

9 years ago

No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx

9 years ago

Eli Lilly wins a quick OK for new sarcoma drug olaratumab

9 years ago

Now that Sarepta has bolted out of the barn, the FDA wants to shut the door

9 years ago

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

9 years ago

Novartis throws Cerulean a lifeline with $5M deal; Porges disses Celgene’s GED-0301

9 years ago

Cancer powerhouse Roche elbows its way into a checkpoint showdown with Bristol-Myers, Merck

9 years ago

Oxford spinout Argonaut looks to hack cancer cells and program them to die

9 years ago

Merck bags a PhIII CMV victory in the wake of a flop at rival Chimerix

9 years ago

Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range

9 years ago

Kite CEO Arie Belldegrun preps for a looming date with the FDA as he tackles first-mover advantage in CAR-T

9 years ago

New Vancouver-based fund has $100M to invest in biotech; FDA hands out $23M in rare disease R&D grants

9 years ago

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

9 years ago

Nancy Stagliano bags another $45M for True North’s rare disease R&D

9 years ago

Armed antibody player ADC lands a $105M mega-round to back pipeline construction

9 years ago

First page Previous page 1150 1151 115211531154 1155 1156 Next page Last page